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Abstract
Topical hemostatic agents are applied locally to areas of injured vascular endothelium to control local bleeding.
Ankaferd Blood Stopper (ABS) has gained approval in Turkey and Bosnia-Herzegovina as a topical haemostatic agent for
external post-surgical and post-dental surgery bleeding. The safety of topical use of ABS has been demonstrated in
numerous in vitro and in vivo animal models, as well as in a clinical Phase I trial in humans. ABS, besides its haemostatic
activity, also has in vitro anti-infectious and anti-neoplastic effects. To assess potential detrimental effects of intravenous
administration of ABS into intact systemic circulation in a rabbit experimental model, one milliliter of ABS was administered
intravenously into the systemic circulation of twelve rabbits which were included in the study via the marginal ear vein.
Animals were observed for 1 hr before euthanasia was performed by administering 40 mg of intracardiac suxamethonium
chloride. In the event of death (cardiopulmonary arrest) before the end of the planned observation period of 60 minutes,
time of death was recorded and histopathological examination of the liver and spleen was commenced. Ten rabbits were
alive by the end of the planned observation period, without showing any clear signs of discomfort, whereas two animals
died within five minutes after systemic administration of intravenous ABS. Postmortem histopathological examination of
the livers and spleens of all animals’ revealed findings consistent with hepatic venous outflow obstruction. Systemic
intravascular administration of ABS into intact vascular endothelium should never be performed in any setting. Further
experimental and clinical studies on this liquid hemostatic agent should proceed by accepting ABS as purely a topical
haemostatic agent, to be applied solely to areas of injured vascular endothelium.
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Introduction
Ankaferd Blood Stopper (ABS) is a standardized herbal extract obtained from five different plants Thymus vulgaris,
Glycyrrhiza glabra, Vitis vinifera, Alpinia officinarum, and Urtica dioica (Firat et al., 2009). ABS represents its unique local
haemostatic effect by promoting the very rapid (<1 s) formation of a protein network which acts as an anchor for vital
physiological erythrocyte aggregation, covering the classical cascade model of the clotting system without independently
acting on coagulation factors and platelets (Goker et al., 2008a). ABS has been approved for local topical applications in
dermal, external post-surgical and dental bleeding in Turkey and Bosnia-Herzegovina (Ercetin et al., 2010). ABS has been
shown to be an effective hemostatic agent in both in vivo and in vitro studies (Goker et al., 2008a; Bilgili et al., 2009; Cipil et
al., 2009; Huri et al., 2009a; Karakaya et al., 2009; Kosar et al., 2009; Ercetin et al., 2010). Bacteriostatic effects on gram
positive and gram negative bacteria have also been demonstrated (Tasdelen Fisgin et al., 2009). It is currently approved for
use in external and dental surgical bleeding (Ercetin et al., 2010). Its efficacy and safety as a haemostatic agent in dental
surgery has been well documented, while at the same time contributing to wound healing (Baykul et al., 2010; Ercetin et al.,
2010).
ABS has been used in the setting of gastrointestinal bleeding both as an adjuvant haemostatic agent and as a last
resort where other conventional methods had failed (Ibis et al., 2008; Kurt et al., 2008a; Kurt et al., 2008b; Kurt et al., 2009;
Ozaslan et al., 2009; Kurt et al., 2010). In these studies, the efficacy of ABS was once again demonstrated, particularly for
bleeding from GIS tumors (Kurt et al., 2010). Furthermore, in two patients a decrease in tumoral microvessel density was
observed, which may indicate a possible anti-angiogenic effect of ABS (Turhan et al., 2009). Similarly, ABS was beneficial in
the management of chronic bleeding due to a solitary rectal ulcer (Ibis et al., 2008). Its efficacy was once again proven in a
Klatskin tumor patient with severe GIS bleeding and epistaxis (Kurt et al., 2009). It has also been utilized as a bridge to
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cyanoacrylate injection in a patient with active bleeding from a fundal varix (Tuncer et al., 2010). It has also been shown to
be more effective than standard sterile sponges for controlling bleeding during port insertion, as well as being associated
with lower rebleeding rates (Al et al., 2009). A recent study reported on an advantage of ABS over conventional methods in
decreasing bleeding and shortening operation time in children undergoing tonsillectomies (Teker et al., 2009). It has also
been used with success in a young girl with afibrinogenemia who presented with a finger cut (Ucar Albayrak et al., 2008).
Favorable results have also been reported for prostatectomy (Huri et al., 2009b). ABS, besides its hemostatic activity, has
also in vitro anti-neoplastic actions (Goker et al., 2008b; Goker et al., 2008c).
The safety of ABS has not yet been equivocally established, and its mechanism of action prompts serious concerns
regarding a possible risk associated with intravenous leakage of the substance following gastrointestinal application. The
aim of this study was to assess potential harmful effects of intravenous administration of ABS into intact systemic
circulation in an experimental rabbit model.
Materials and methods
This experimental study was conducted with the approval of the Fatih University Medical School Ethics
Committee. All procedures were in full compliance with Turkish Law 6343/2, Veterinary Medicine Deontology Regulation
6.7.26 and with the Helsinki Declaration of World Medical Association recommendations on animal studies.
Twelve rabbits, housed in metal cages with a wire netting bottom, maintained at a temperature of 23ºC ( 5ºC),
were used in this study. The animals were allowed free access to a solid diet and tap water, and were allowed to roam
freely for an hr in a small garden, twice daily.
Experimental design
Each of the rabbits, which were randomly assigned a number from 1-12, were weighed. Estimated total blood
volume was calculated for each rabbit using the formula (60 ml x weight in kilograms), after which 1 ml of ABS was
administered intravenously via the marginal ear vein. Animals were observed for 1 hr before euthanasia was performed by
administering 40 mg of intracardiac suxamethonium chloride. In the event of death (cardiopulmonary arrest) before the
end of the planned observation period of 60 mins, time of death was recorded and histopathological examination of the
liver and spleen was commenced, performed by the same experienced pathologist (NT).
Table 1.Characteristics of the rabbits and histopathological findings











1 3900 4.598 0.256
2 3100 5.9 0.323
3 2900 6.349 0.345
4 2850 6.472 0.351
5 2900 6.349 0.345
6 4500 3.945 0.222
7 2350 8.032 0.425
 Sinusoidal dilatation and congestion (Rabbits 1-10)
 Marked dilatation and congestion of the central and portal
veins (All rabbits)
 Early signs of perivenular necrosis (Rabbit 7)
 Intraparenchymal herniation of a some of the central and
portal veins (Rabbits 2-4, 6, 9-12)
 Eosinophilic mass resembling fragmented erythrocytes,
particularly within veins (All except rabbit 5)
 Small- large subcapsular foci of confluent coagulative necrosis
(Rabbits 2, 6-9,10-12)
 Marked periductal inflammation, with lymphocytic infiltration
of the biliary ductal epithelium (cholangitis) (Rabbit 4)
 Hepatocellular cholestasis (Rabbit 6,9-11)
8 2400 7.843 0.417
SPLEEN
9 3500 5.168 0.286
10 4200 4.246 0.238
11 3700 4.866 0.270
12 3600 5.013 0.278
 All rabbits had signs of mild splenic congestion.
 Subcapsular necrosis (Rabbits 10-12)
* TBV: Total Blood Volume
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Results
The characteristics of the rabbits and histopathological findings were summarized in table 1. The median weight of
the animals was 3300 gr (2350-4500 gr). Animals 7 (2350 gr) and 8 (2400 gr) died within 5 minutes of administration of
intravenous ABS, during which time they were in obvious distress. These two were the smallest rabbits of the study group.
The remaining animals were still alive by the end of the planned observation period, without showing any clear signs of
discomfort.
Pericentral congestion and sinusoidal dilatation, as well as varying levels of necroinflammation and coagulative
necrosis were observed in the livers of all the animals, findings consistent with acute hepatic venous outflow obstruction,
which in these cases was most probably due to congestive hepatopathy occuring as a result of right-sided heart failure
(acute cor pulmonale) (Figure 1). Rabbit no. 4 had findings consistent with cholangitis. However, this was most likely
unrelated to ABS administration as structures resembling bile stones were observed in the biliary tree.
Similarly histopathological examination of the spleens of all animals revealed signs consistent with mild
congestion, probably as a result of portal hypertension.
Figure 1. Histopathological examinations revealed A: Necrosis around the central vein. B: Eosinophilic mass. C: Cholangitis.
D: Subcapsular necrosis and congestion of the central and portal veins. E: Intraparenchymal herniation of the
central vein. F: Dilatation of the central vein and hepatocellular cholestasis. G: Sinusoidal dilatation and
congestion. H: Subcapsular necrosis in the spleen. I: Mild splenic congestion.
Discussion
Ankaferd Blood Stopper is a unique standardized mixture of 5 plants: T. vulgaris, G. glabra, V. vinifera, A.
officinarum and U. dioica, each of which has some effect on haematological and vascular parameters, and cellular
proliferation (Goker et al., 2008a). Traditionally, these plant extracts have been used in fixed proportions (2 ml product
contains; Urtica dioica (dried root extract) 0.12 mg, Vitis vinifera (dried leaf extract) 0.16 mg, Glycrrhiza glabra (dried leaf
extract) 0.18 mg, Alpinia officinarum (dried leaf extract) 0.14 mg, Thymus vulgaris (dried grass extract) 0.1 mg) for the
control of external bleeding from the skin (Firat et al., 2009). In earlier studies, the use of each of these extracts separately
failed to demonstrate a meaningful haemostatic effect. Interestingly, this combination of all five plants in ABS appears to
provide a unique composition promoting tissue oxygenation as well as initializing a physiological haemostatic process
without involving any individual clotting factor (Goker et al., 2008a).
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Extracts from several plants, such as Sanguisorba officinalis, Sophora japonica, Nelumbo nucifera have been
shown to have haemostatic effects to varying degrees (Liao et al., 2008). However, in comparison, ABS as a traditional
Turkish herbal medicine extract seems to have more practical implications in the field of medicine, particularly for the
control of gastrointestinal bleeding.
There is a growing body of evidence on the efficacy of ABS as a haemostatic agent in several clinical settings,
including the control of bleeding due to gastrointestinal cancers, mediastinal bleeding, haemorrhage after retropubic radical
prostatectomy and post-tonsillectomy bleeding (Dogan et al., 2008; Ibis et al., 2008; Kurt et al., 2008a; Kurt et al., 2008b; Al
et al., 2009; Arslan et al., 2009; Huri et al., 2009b; Kurt et al., 2009; Ozaslan et al., 2009; Teker et al., 2009; Baykul et al.,
2010; Ercetin et al., 2010; Kurt et al., 2010; Tuncer et al., 2010). With special relevance to the gastrointestinal system,
heater probe coagulation, sclerotherapy, haemoclips and argon plasma photocoagulation are the conventional and well
established methods for haemostasis, As an herbal extract, ABS offers an advantage due to ease of application as well as
efficacy in more challenging clinical settings such as malignant gastrointestinal bleeding, where none of the conventional
methods has proved effective (Kurt et al., 2010). Although results so far have been very promising, lack of concrete data on
the safety of ABS remains a serious concern. Application of ABS on compromised mucosa with exposed blood vessels runs
the risk of accidental intravenous leakage, and subsequently systemic embolic complications.
In this rabbit model, blood in the marginal ear vein flows to the external jugular vein via the maxillary vein, after
which it reaches the right atrium via the cranial vena cava. From there, blood is pumped to the right ventricle and into the
pulmonary arteries, and subsequently the pulmonary capillary bed. When the mechanism of action of the haemostatic
agent is taken into consideration, it is fair to expect ABS administered through the marginal ear vein to instantaneously
result in formation of an “ABS-web” which would eventually get lodged in the pulmonary arteries / pulmonary capillary bed.
Evaluation of ensuing hemodynamic instability and hypoxia could not realistically be evaluated in this rabbit model as it
would have required invasive catheterization and monitoring. Simply demonstrating the presence of pulmonary emboli by
histopathological examination of the lungs would not have sufficed, since it was essential to demonstrate any potential
effects on haemodynamic, particularly acute cor pulmonale. For this purpose, histopathological examination of the liver and
spleen was performed on the assumption that elevation in right heart and subsequently caudal vena cava pressure would
result in liver congestion, and thus resulting in portal hypertension, and congestion of the spleen as well. Indeed, our results
confirmed the presence of such findings.
The early deaths of the two rabbits in this study, as well as the histopathological findings of the surviving animals
should be a reminder about the grave consequences of systemic placement of this topical haemostatic agent into intact
systemic circulation. Systemic intravascular administration of ABS into intact vascular endothelium should never be
performed under any circumstance. Further experimental and clinical studies on this liquid hemostatic agent should
proceed by accepting ABS in the concept of topical hemostatic agent to be applied solely to the areas of injured vascular
endothelium at the bleeding source.
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